Clinical Trials Sponsored by Kastle Therapeutics, LLC

Total 425 results

Kastle Therapeutics, LLC

Completed

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)

Hypercholesterolemia | Heterozygous Familial

United States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Hypercholesterolemia | Coronary Heart Disease

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers

Healthy Volunteer

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects (ASSIST)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic Disorder

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (RADICHOL II)

Coronary Artery Disease | Heterozygous Familial Hypercholesterolemia

United States, Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia (RADICHOL 1)

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditions

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Hypercholesterolemia | Coronary Heart Disease

South Africa, Germany, United States, United Kingdom, Canada, Czech Republic
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Healthy Volunteer

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Castle Creek Biosciences, LLC.

Active, not recruiting

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (DEFI-RDEB)

Recessive Dystrophic Epidermolysis Bullosa

United States
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Scleroderma, Localized | Morphea | Scleroderma

United States
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa Dystrophica, Recessive

United States
Castle Creek Biosciences, LLC.

Terminated

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

Restrictive Burn Scars

United States
Castle Creek Biosciences, LLC.

Completed

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

Interdental Papillary Insufficiency

United States
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Castle Creek Pharmaceuticals, LLC

Completed

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Epidermolysis Bullosa | Epidermolysis Bullosa Simplex

United States
Castle Creek Pharmaceuticals, LLC

Completed

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Healthy

United States
Castle Creek Pharmaceuticals, LLC

Completed

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

Healthy

United States
Castle Creek Pharmaceuticals, LLC

Completed

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

Healthy

United States
Castle Creek Biosciences, LLC.

Withdrawn

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

Restrictive Burn Scars of Joint Area

United States
Castle Creek Biosciences, LLC.

Completed

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

Dysphonia Resulting From Vocal Fold Scarring | Age-related Dysphonia

United States
Castle Creek Pharmaceuticals, LLC

Completed

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Dystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)

United States
Castle Creek Biosciences, LLC.

Completed

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

Acne Scarring of the Face

United States
Castle Creek Biosciences, LLC.

Completed

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

Bilateral Nasolabial Fold Wrinkles

United States
Castle Creek Biosciences, LLC.

Completed

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

Bilateral Nasolabial Fold Wrinkles

United States
Castle Creek Biosciences, LLC.

Completed

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases

Facial Wrinkles and Creases

United States
Castle Creek Pharmaceuticals, LLC
TKL Research, Inc.

Completed

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

Healthy

United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
Constant Therapeutics LLC

Recruiting

Phase 2 Study of TXA127 in Post-ischemic Stroke Patients

Ischemic Stroke

Israel
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia

Bacterial Infections | B-cell Chronic Lymphocytic Leukemia | Hypogammaglobulinemia

United States, Bulgaria, Poland, Romania, Serbia
Minneamrita Therapeutics LLC

Recruiting

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Gastric Cancer

Korea, Republic of
Cerevel Therapeutics, LLC

Recruiting

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Opioid Use Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Cardix Therapeutics LLC

Not yet recruiting

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Bradycardia
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Cloudbreak Therapeutics, LLC

Completed

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Cerevel Therapeutics, LLC

Completed

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Healthy Volunteers

United States
Cerebral Therapeutics LLC

Terminated

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

Refractory Epilepsy

Israel, Australia
Cerevel Therapeutics, LLC

Active, not recruiting

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Parkinson Disease

Spain, United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Healthy Participants

United States

Clinical Trials Sponsored by Kastle Therapeutics, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations